On the way towards a new kind of intelligent chemotherapy:

Düsseldorf/Münster, August 15, 2017

CellAct Pharma GmbH, Dortmund/Germany, a biotech company financed by NRW.BANK, has sold development, production and commercialisation rights to the Mundipharma network of independent associated companies. The international pharmaceutical company network has acquired the rights in the total amount of over USD 250 million and will now continue the clinical development of the drug.  

“Through its multi-year investment, NRW.BANK has financed the development of a promising drug for the treatment of seriously ill cancer patients,” says Michael Stölting, member of the development bank’s Managing Board. “Mundipharma is a strong and experienced partner who is able to take the drug forward to the next stage of clinical development and to get it ready for marketing.”

Named “CAP7.1”, the newly developed drug represents a new kind of “intelligent chemotherapy” that is unique throughout the world. “CAP7.1” was discovered at Charité – Universitätsmedizin Berlin. CellAct developed the drug from the preclinical state to clinical phase 2 and demonstrated a targeted chemotherapeutic treatment of cancer cells in the biliary tract.

Since 2007, NRW.BANK has held a share in CellAct Pharma GmbH through its venture fund together with Peppermint Venture and SeedCapital Dortmund. The NRW.BANK.Venture Fund makes equity capital available to North Rhine-Westphalian companies with high growth potential to finance their expansion. The fund places a special focus on sectors such as software/IT, media, life sciences and cleantech.

For more information, visit www.nrwbank.de/venturefonds. Follow us on www.twitter.com/NRWBANK

NRW.BANK is the state development bank of North Rhine-Westphalia. Its mission is to support its owner – the state of North Rhine-Westphalia – in the completion of its structural and economic policy tasks. In its three fields of promotion “Economic Development”, “Housing Promotion” and “Infrastructure/Municipal Promotion”, NRW.BANK uses a wide range of promotion tools – from low-interest promotion loans to equity financing to advisory services. It cooperates with all banks and savings banks based in NRW on a competition-neutral basis. NRW.BANK takes into account the existing offers by the Federal Government, the North Rhine-Westphalian government and the European Union in the arrangement of its promotion.



Press Officer

Tel.:+49 211 91741 - 1847

Fax:+49 211 91741 - 1260


Ihre Anfrage

* Mandatory fields Your e-mail address and the e-mail address of the recipient/s are used solely for the purposes of data transfer and then deleted.


Your rating

If you have a question or concern and would prefer to contact the NRW.BANK in person, please use one of our contact options.